Crossmark Global Holdings Inc. Purchases Shares of 6,167 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Crossmark Global Holdings Inc. purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 6,167 shares of the biotechnology company’s stock, valued at approximately $975,000.

A number of other large investors have also recently bought and sold shares of SRPT. Principal Securities Inc. bought a new stake in Sarepta Therapeutics in the fourth quarter valued at $26,000. Mather Group LLC. acquired a new position in Sarepta Therapeutics in the first quarter worth $28,000. Riggs Asset Managment Co. Inc. boosted its stake in Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 125 shares in the last quarter. Innealta Capital LLC acquired a new position in Sarepta Therapeutics in the second quarter worth $31,000. Finally, New Covenant Trust Company N.A. acquired a new position in Sarepta Therapeutics in the first quarter worth $32,000. 86.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Bilal Arif sold 7,859 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the transaction, the insider now directly owns 21,261 shares in the company, valued at $3,467,243.88. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Bilal Arif sold 7,859 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the transaction, the insider now directly owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total value of $6,295,840.77. Following the transaction, the executive vice president now directly owns 17,129 shares of the company’s stock, valued at $2,768,217.69. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on SRPT. Citigroup cut their price target on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Morgan Stanley reaffirmed an “overweight” rating and set a $165.00 price target on shares of Sarepta Therapeutics in a research note on Friday, June 21st. BMO Capital Markets upped their price target on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Monday, June 24th. Piper Sandler cut their price target on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Finally, Leerink Partners increased their target price on Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, June 24th. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $186.22.

Sarepta Therapeutics Stock Down 1.1 %

Shares of Sarepta Therapeutics stock opened at $135.78 on Friday. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $173.25. The business has a 50-day moving average of $145.03 and a two-hundred day moving average of $133.00. The company has a market capitalization of $12.83 billion, a P/E ratio of 1,234.36 and a beta of 0.89. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The business had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. Sarepta Therapeutics’s quarterly revenue was up 38.9% on a year-over-year basis. During the same period last year, the company earned ($0.27) earnings per share. As a group, equities analysts predict that Sarepta Therapeutics, Inc. will post 3.76 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.